A 16-year-old girl presents with primary amenorrhea. On examination, she has normal secondary sexual characteristics, normal external genitalia, and a blind-ending vaginal pouch. Imaging confirms absent uterus and fallopian tubes with normal ovaries. What is the drug of choice for hormone replacement in this patient?

Explanation

## Clinical Scenario: Müllerian Agenesis (Mayer–Rokitansky–Küster–Hauser Syndrome) This patient has **primary amenorrhea with normal secondary sexual characteristics, absent uterus and fallopian tubes, and normal ovaries** — a classic presentation of **MRKH (Mayer–Rokitansky–Küster–Hauser) syndrome**, also called Müllerian agenesis. ### Pathophysiology In MRKH syndrome, the Müllerian (paramesonephric) ducts fail to develop, resulting in absence of the uterus, cervix, and upper vagina. The ovaries are **normal and functional**, producing physiological levels of estrogen and progesterone. Hence, secondary sexual characteristics develop normally and the karyotype is 46,XX. ### Hormone Replacement Rationale **Key Point:** Because the ovaries are intact and functional in MRKH syndrome, patients do **not** require routine exogenous HRT. However, when HRT is indicated (e.g., co-existing premature ovarian insufficiency or surgical oophorectomy), the drug of choice is **conjugated estrogens alone** — because there is **no endometrium**, progestin is not needed and is not indicated. **High-Yield:** The critical distinction in MRKH: - **Progestin is added in HRT solely to protect the endometrium** from unopposed estrogen-induced hyperplasia/carcinoma - In MRKH, there is **no uterus and no endometrium** — therefore, progestin has no protective role and is **not required** - **Estrogen alone** is the appropriate and sufficient regimen, providing bone mineral density protection, cardiovascular benefit, and psychological well-being - Adding progestin unnecessarily exposes the patient to its side effects (mood changes, metabolic effects) without benefit > **Textbook Reference:** Shaw's Textbook of Gynaecology (17e) and Williams Obstetrics (26e) both state that in women without a uterus, estrogen-only HRT is the standard of care. Progestin is added only when a uterus (and endometrium) is present. ### Why NOT Other Options? | Option | Reason for Rejection | |--------|---------------------| | **Estrogen + progestin cyclic regimen** | Progestin is unnecessary in the absence of a uterus/endometrium; adds side effects without benefit. This regimen is used when the uterus is intact. | | **Progestin alone** | Insufficient for bone protection and cardiovascular health; estrogen is the primary agent for these outcomes. | | **Testosterone** | Inappropriate; the patient has normal 46,XX karyotype, normal ovarian function, and normal secondary sexual characteristics. Testosterone is used in androgen deficiency states (e.g., complete androgen insensitivity syndrome or male hypogonadism). | **Clinical Pearl:** Patients with MRKH syndrome can achieve biological parenthood through IVF with gestational surrogacy or, in specialized centers, uterine transplantation. Vaginal creation (Frank's progressive dilation or surgical vaginoplasty) is the primary treatment for the vaginal anomaly. When HRT is given, **estrogen alone** is the drug of choice — the absence of a uterus removes the rationale for progestin entirely. [cite: Shaw's Textbook of Gynaecology 17e, Ch 20; Williams Obstetrics 26e, Ch 32; KD Tripathi Essentials of Medical Pharmacology 8e]